LRRK2 COHORT CONSORTIUM BIOSPECIMENS USE AGREEMENT
(“Biospecimens Use Agreement”)

I request access to biospecimens collected by The MJFF LRRK2 Cohort Consortium (LCC) for the purpose of scientific investigation and agree to the following terms of the LRRK2 Biospecimens Use Policy:

LRRK2 Cohort Consortium Biospecimens Use Policy

Access to biospecimens collected by the LCC (“Biospecimens”) will be granted according to procedures set forth by the LCC Biospecimen Resource Access Committee (BRAC) and in compliance with this LRRK2 Biospecimen Use Policy (“Policy”):

1. All access to Biospecimens must be approved in advance by the BRAC. Such approval will be granted to scientific researchers, including employees or independent contractors working under the direction of such scientific researchers, and the (non-profit or for-profit) institutions at which approved scientists will conduct their research (“Recipients”).

2. Recipients will be required to agree to the terms and conditions of this Policy prior to receiving access to Biospecimens.

3. Access to Biospecimens will be granted by the BRAC only for scientific research purposes, which may include testing research tools, therapies or cures for commercialization. Requestors will submit a proposal requesting access to Biospecimens, which will include, among other things, a description of the intended research use of the Biospecimens.

4. Recipients must agree to comply with all rules and regulations imposed by institutions at which Recipients will use the Biospecimens, including institution review board (IRB) policies and procedures.

5. Data associated with Biospecimens are de-identified. Access to Biospecimens will be granted only on the condition that Recipients will not attempt to establish the identity of, or attempt to contact, study subjects participating in the LCC.

6. Biospecimens will be shipped from the LCC biorepositories to the receiving investigator in a blinded fashion. The samples are matched to a unique identification number (“ID”). When the analyses are completed, the investigator will submit a report of the analyses by subject to the LCC Biorepository for reconciliation with the sample manifest and to LCC database for unblinding. The LCC database will provide a “code” that will match the unique ID with the LCC ID so the specimens can then be unblinded and investigators can match the Biospecimens data to the clinical data in the LCC database. Within 45 days of unblinding, all investigators who use LCC samples must submit his/her quality-checked data/analyses to MJFF. Upon submission, MJFF has the right, but not the obligation, to deposit these analyses in the LCC study database for use by the research community.

Revision date: March 2016
7. Biospecimens may not be used:
   a. for any purposes other than as outlined in a Recipient’s proposal for access; or
   b. in any way that conflicts with this Policy.

   During any time that Recipient is in possession of one or more Biospecimens, Recipients must report:
   c. any important changes to the research purposes; or
   d. changes to the Principal Investigator (PI) in charge of the Biospecimens, which will require
      advance approval from MJFF.

8. Biospecimens may not be shared by Recipients with anyone not affiliated with the Recipient
   institution (each, a “Third Party”), unless advance approval is obtained from MJFF, the proposed
   Third Party is participating in the research identified in the Recipient’s application for access to the
   Biospecimen(s) and the Third Party agrees in writing to be bound by this Policy.

9. Recipients must respond promptly and accurately to annual requests for updates on use of
   Biospecimens and the progress of the research for which any Biospecimen is used.

10. No Recipient or institution receiving Biospecimens may claim any intellectual property (IP) rights,
     including, without limitation, patent, copyright, trademark or trade secrets in Biospecimens or data
     associated with Biospecimens. Neither MJFF nor the LCC may claim IP rights in any
     Biospecimens.

11. No Recipient or institution using Biospecimens may claim any IP rights for any invention or new
     work created in whole or part from Recipient’s use of Biospecimens or associated data. Recipients
     will agree to use their best efforts to publicize to the research community any invention or new work
     useful to Parkinson’s disease researchers created in whole or part from Biospecimens or associated
     data, including contacting MJFF for assistance in publicizing such invention or new work. This
     Section 11 shall not preclude any Recipient from claiming IP rights to any invention or work not
     involving in any way Recipient’s use of Biospecimens (“Background IP”), even if the Biospecimens
     are used to test or analyze the Background IP. Any such Background IP should be identified on
     Recipients’ proposal requesting access to Biospecimens.

12. Any IP claim in violation of Sections 10 or 11 of this Policy shall be void, and Recipient agrees
     to withdraw any improperly filed IP claim, whether such claim is filed in a court, to a
     government agency and/or with a private party.

13. All manuscripts and abstracts/posters using data from the LCC and/or data generated from analyses
     using Biospecimens (“Data”) will comply with the guidelines established and written out in the
     LRRK2 Cohort Consortium Publications Policy, including the following:

     a. All manuscripts and abstracts/posters using Data shall be made freely available to the
        scientific research community without charge, including, at MJFF’s election, through a
        website maintained by MJFF, unless accepted for publication by a journal of established
        reputation in the scientific community not controlled by Recipient whose publication policies
        conflict with this Section 13, in which case such publication may be in accordance with the
        policies of the journal.

     b. All manuscripts and abstracts/posters using Data and/or Biospecimens will acknowledge the
        LCC and MJFF in the following ways:

                   2

Revision date: March 2016
i. All manuscripts using Data will acknowledge the methods of LCC data gathering using the following language recommended by the LCC:

“Data used in preparation of this article were obtained from the MJFF-sponsored LRRK2 Cohort Consortium (LCC). For up-to-date information on the study, visit www.michaeljfox.org/lcc.”

ii. All manuscripts using Biospecimen will acknowledge the methods of the LCC using the following language recommended by the LCC:

“Biospecimen used in the analyses presented in this article were obtained from the MJFF-sponsored LRRK2 Cohort Consortium (LCC). For up-to-date information on the study, visit www.michaeljfox.org/lcc.”

iii. All manuscripts will acknowledge the support of MJFF using language similar to the following:

“The LRRK2 Cohort Consortium is coordinated and funded by The Michael J. Fox Foundation for Parkinson’s Research.”

iv. All manuscripts will appropriately acknowledge the members of the LCC (see Publication Policy for guidelines depending on publication type).

c. All manuscripts and abstracts/posters using Data and/or Biospecimens will be submitted to MJFF two weeks prior to submission to a journal so that MJFF may verify that Recipient has complied with this Section 13. MJFF may share the publication, presentation or analysis with the SC. MJFF and the LCC will maintain confidentiality of the manuscript and will complete its review within one week of submission.

d. Full citation of all published manuscripts and abstracts/posters using Data and/or Biospecimens will be provided to MJFF and the LCC upon acceptance to a journal or conference by emailing a copy of the manuscript or abstract/poster to resources@michaeljfox.org.

14. Unused Biospecimens or portions thereof will, at the election of MJFF, be returned to the LCC Biorepository or destroyed. Recipients must notify MJFF promptly upon completion of the research identified in the application or any amendments thereto.

15. Recipients will use appropriate administrative, physical and technical safeguards to prevent use or disclosure of the Data other than as provided for in this Biospecimens Use Agreement.

16. Any violation of this Policy by a Recipient must be promptly reported to MJFF and may at MJFF’s election, result in termination of Recipient’s access to Biospecimens and the return of such Biospecimen to the LCC Biorepository.

17. I agree to report any use or disclosure of the Biospecimens not provided for by this Policy of which I become aware within 15 days of becoming aware of such use or disclosure.

(Signature on Following Page)
I agree to report any use or disclosure of the Biospecimens not provided for by this Policy of which I become aware within 15 days of becoming aware of such use or disclosure.

I will ensure that any Recipients who utilize Biospecimens use appropriate and administrative, physical and technical safeguards to prevent use of the Biospecimens other than as provided for by this Biospecimens Use Agreement and as outlined in the application protocol.

I agree to the terms of this Policy as well as any changes to this Policy that MJFF may adopt, unless such changes hamper my work. If that is the case, I agree to contact MJFF to discuss such changes to understand the best way to proceed without violating terms of the Policy as amended.

I understand that failure to abide by this agreement will result in termination of my privileges to access Data and/or Biospecimens.

________________________________________________________________________

(Signature)

________________________________________________________________________

(Print Name)

________________________________________________________________________

(Date of signature)